Guided Thera Financials
This page shows Guided Thera (GTHP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Tiny sales sit beside a persistent cash burn, so external funding still matters more than operating scale.
After revenue rebounded from$7K in FY2024 to$767K in FY2025, the business still used cash at nearly the same rate, showing that higher sales have not yet covered the fixed cost base. That is why a strong74.5% gross margin could coexist with operating cash flow of-$1.07M : unit economics improved, but company-level economics are still dominated by overhead and financing needs.
Liquidity tightened in FY2025 because financing inflows of
Working capital is not very liquid: inventory was
Financial Health Signals
We are recalculating Guided Thera's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.
Guided Thera scores -174.50, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($29.0M) relative to total liabilities ($7.3M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Guided Thera passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Guided Thera generates $0.33 in operating cash flow (-$1.1M OCF vs -$3.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Guided Thera earns $-3.8 in operating income for every $1 of interest expense (-$2.4M vs $617K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Guided Thera generated $767K in revenue in fiscal year 2025. This represents an increase of 10857.1% from the prior year.
Guided Thera's EBITDA was -$2.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 12.5% from the prior year.
Guided Thera reported -$3.2M in net income in fiscal year 2025. This represents a decrease of 32.2% from the prior year.
Guided Thera earned $-0.04 per diluted share (EPS) in fiscal year 2025. This represents an increase of 20.0% from the prior year.
Cash & Balance Sheet
Guided Thera generated -$1.1M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 4.4% from the prior year.
Guided Thera held $63K in cash against $0 in long-term debt as of fiscal year 2025.
Guided Thera had 86M shares outstanding in fiscal year 2025. This represents an increase of 32.3% from the prior year.
Margins & Returns
Guided Thera's gross margin was 74.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 45.9 percentage points from the prior year.
Guided Thera's operating margin was -309.3% in fiscal year 2025, reflecting core business profitability. This is up 29805.0 percentage points from the prior year.
Guided Thera's net profit margin was -416.7% in fiscal year 2025, showing the share of revenue converted to profit. This is up 34111.9 percentage points from the prior year.
Capital Allocation
Guided Thera invested $469K in research and development in fiscal year 2025. This represents a decrease of 10.8% from the prior year.
Guided Thera invested $2K in capex in fiscal year 2025, funding long-term assets and infrastructure.
GTHP Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | N/A | $60K-48.7% | $117K | $0 | N/A | $0 | $0 |
| Cost of Revenue | $0 | N/A | $25K-34.2% | $38K | $0 | N/A | $0 | $0 |
| Gross Profit | $0 | N/A | $35K-55.7% | $79K | $0 | N/A | $0 | $0 |
| R&D Expenses | $45K | N/A | $136K+2.3% | $133K+79.7% | $74K | N/A | $111K-50.0% | $222K |
| SG&A Expenses | $451K | N/A | $362K-45.0% | $658K+146.4% | $267K | N/A | $374K+2.7% | $364K |
| Operating Income | -$302K | N/A | -$485K+36.4% | -$763K-84.3% | -$414K | N/A | -$561K+14.4% | -$655K |
| Interest Expense | $151K | N/A | $129K-17.8% | $157K+6.8% | $147K | N/A | $108K+44.0% | $75K |
| Income Tax | $0 | N/A | $0 | $0 | $0 | N/A | $0 | $0 |
| Net Income | -$500K | N/A | -$742K+8.5% | -$811K-89.9% | -$427K | N/A | -$654K+7.8% | -$709K |
| EPS (Diluted) | $-0.01 | N/A | $-0.010.0% | $-0.010.0% | $-0.01 | N/A | $-0.010.0% | $-0.01 |
GTHP Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.6M+21.1% | $1.3M+46.6% | $903K-3.9% | $940K-2.8% | $967K-29.8% | $1.4M+10.3% | $1.2M-0.2% | $1.3M |
| Current Assets | $911K+50.6% | $605K-24.3% | $799K-1.5% | $811K0.0% | $811K-32.2% | $1.2M+14.8% | $1.0M+2.2% | $1.0M |
| Cash & Equivalents | $369K+485.7% | $63K-27.6% | $87K-53.0% | $185K+60.9% | $115K-70.4% | $388K+100.0% | $194K-29.5% | $275K |
| Inventory | $469K+4.7% | $448K-23.2% | $583K-2.0% | $595K-6.0% | $633K0.0% | $633K-0.5% | $636K+0.6% | $632K |
| Accounts Receivable | $4K0.0% | $4K-33.3% | $6K-25.0% | $8K+300.0% | $2K-33.3% | $3K+50.0% | $2K0.0% | $2K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $6.8M-7.5% | $7.3M+11.9% | $6.5M+2.1% | $6.4M+7.0% | $6.0M-4.3% | $6.3M+1.6% | $6.2M+4.2% | $5.9M |
| Current Liabilities | $6.0M-10.2% | $6.6M+2.6% | $6.5M+1.5% | $6.4M+8.1% | $5.9M-4.2% | $6.2M+2.2% | $6.0M+5.1% | $5.7M |
| Long-Term Debt | $91K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$5.2M+13.8% | -$6.0M-6.4% | -$5.6M-3.2% | -$5.5M-8.8% | -$5.0M-2.8% | -$4.9M+0.6% | -$4.9M-5.4% | -$4.7M |
| Retained Earnings | -$158.1M-0.6% | -$157.1M-0.8% | -$155.8M-0.5% | -$155.0M-0.6% | -$154.2M-0.3% | -$153.7M-0.5% | -$153.0M-0.5% | -$152.3M |
GTHP Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$617K-112.0% | -$291K-5.1% | -$277K-63.9% | -$169K+48.9% | -$331K+0.3% | -$332K+29.8% | -$473K-121.0% | -$214K |
| Capital Expenditures | N/A | $0 | N/A | N/A | N/A | $0 | N/A | N/A |
| Free Cash Flow | N/A | -$291K | N/A | N/A | N/A | -$332K | N/A | N/A |
| Investing Cash Flow | N/A | $0 | N/A | N/A | N/A | $0 | N/A | N/A |
| Financing Cash Flow | $923K+245.7% | $267K+47.5% | $181K-24.3% | $239K+312.1% | $58K-89.0% | $526K+34.2% | $392K+790.9% | $44K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
GTHP Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | 58.3%-9.2pp | 67.5% | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | -808.3%-156.2pp | -652.1% | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | -1236.7%-543.5pp | -693.2% | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -31.2% | N/A | -82.2%+4.1pp | -86.3%-42.1pp | -44.2% | N/A | -52.4%+4.3pp | -56.7% |
| Current Ratio | 0.15+0.1 | 0.09-0.0 | 0.120.0 | 0.13-0.0 | 0.14-0.1 | 0.19+0.0 | 0.170.0 | 0.18 |
| Debt-to-Equity | -0.02+1.2 | -1.22-0.1 | -1.16+0.0 | -1.17+0.0 | -1.19+0.1 | -1.28-0.0 | -1.25+0.0 | -1.27 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$6.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.09), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Guided Thera's annual revenue?
Guided Thera (GTHP) reported $767K in total revenue for fiscal year 2025. This represents a 10857.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Guided Thera's revenue growing?
Guided Thera (GTHP) revenue grew by 10857.1% year-over-year, from $7K to $767K in fiscal year 2025.
Is Guided Thera profitable?
No, Guided Thera (GTHP) reported a net income of -$3.2M in fiscal year 2025, with a net profit margin of -416.7%.
What is Guided Thera's EBITDA?
Guided Thera (GTHP) had EBITDA of -$2.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Guided Thera's gross margin?
Guided Thera (GTHP) had a gross margin of 74.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Guided Thera's operating margin?
Guided Thera (GTHP) had an operating margin of -309.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Guided Thera's net profit margin?
Guided Thera (GTHP) had a net profit margin of -416.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Guided Thera's free cash flow?
Guided Thera (GTHP) generated -$1.1M in free cash flow during fiscal year 2025. This represents a 4.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Guided Thera's operating cash flow?
Guided Thera (GTHP) generated -$1.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Guided Thera's total assets?
Guided Thera (GTHP) had $1.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Guided Thera's capital expenditures?
Guided Thera (GTHP) invested $2K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Guided Thera spend on research and development?
Guided Thera (GTHP) invested $469K in research and development during fiscal year 2025.
What is Guided Thera's current ratio?
Guided Thera (GTHP) had a current ratio of 0.09 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Guided Thera's debt-to-equity ratio?
Guided Thera (GTHP) had a debt-to-equity ratio of -1.22 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Guided Thera's return on assets (ROA)?
Guided Thera (GTHP) had a return on assets of -241.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Guided Thera's cash runway?
Based on fiscal year 2025 data, Guided Thera (GTHP) had $63K in cash against an annual operating cash burn of $1.1M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Guided Thera's debt-to-equity ratio negative or unusual?
Guided Thera (GTHP) has negative shareholder equity of -$6.0M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Guided Thera's Altman Z-Score?
Guided Thera (GTHP) has an Altman Z-Score of -174.50, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Guided Thera's Piotroski F-Score?
Guided Thera (GTHP) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Guided Thera's earnings high quality?
Guided Thera (GTHP) has an earnings quality ratio of 0.33x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Guided Thera cover its interest payments?
Guided Thera (GTHP) has an interest coverage ratio of -3.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.